Research programme: selective serotonin 2A/2C receptor agonists - PharmaciaAlternative Names: PNU-57378E
Latest Information Update: 12 May 2006
At a glance
- Originator Pfizer
- Mechanism of Action Serotonin 2 receptor agonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- No development reported Anxiety disorders
Most Recent Events
- 12 May 2006 No development reported - Preclinical for Anxiety disorders in USA (unspecified route)
- 16 Apr 2003 Pharmacia Corporation has been acquired by, and merged into, Pfizer